Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Patuletin is a methoxylated flavonoid, specifically 6-methoxyquercetin, primarily isolated from the flowers of *Tagetes patula* (French Marigold). It is currently being investigated as a potential antineoplastic agent, particularly for the treatment of cervical cancer. The compound exerts cytotoxic effects on human cervical carcinoma cell lines, such as SiHa (HPV-16) and HeLa (HPV-18), by inducing the intracellular production of reactive oxygen species (ROS). This oxidative stress leads to significant morphological changes and subsequent cell death. Beyond its potential in oncology, patuletin has been documented in scientific literature for its antioxidant, anti-inflammatory, and antimicrobial properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on patuletin.